002424.SZ
Guizhou Bailing Group Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 4.50
+0.22%Year over year
Reported trailing growth
- Revenue
- -9.9%
- EBITDA
- —
- EBIT
- +486.4%
- EPS
- —
- Free cash flow
- +111.8%
- Operating cash flow
- +62.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -4.9%
- EBITDA
- -8.7%
- EBIT
- -20.3%
- Net income
- —
- EPS
- —
- Free cash flow
- +12.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026